It is currently debated whether to use GIPR agonists or -antagonists in combination with GLP-1 agonists to treat obesity and T2D, as both combinations show promising results (Holst and Rosenkilde, 2020; Killion et al., 2020; Min et al., 2020). Here, GIPR is linked to type 2 diabetes mellitus.